prostvac-v/tricom
Vaccineexperimental
Clinical trial activity
16 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2001 (NCT00021424)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- prostvac-f/tricom
- prostvac-v/tricom
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03532217 | Phase 1 | Sep 14, 2018 | Bavarian Nordic, Bristol-Myers Squibb, Prostate Cancer Foundation, Washington University in St. Louis |
| NCT03315871 | Phase 2 | Mar 20, 2018 | National Cancer Institute (NCI) |
| NCT02153918 | Phase 2 | May 14, 2014 | National Cancer Institute (NCI) |
| NCT01875250 | Phase 2 | May 28, 2013 | National Cancer Institute (NCI) |
| NCT01867333 | Phase 2 | May 16, 2013 | National Cancer Institute (NCI) |
| NCT01145508 | Phase 2 | Aug 1, 2010 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT00450463 | Phase 2 | Feb 19, 2007 | National Cancer Institute (NCI) |
| NCT00450619 | Phase 2 | Feb 1, 2007 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00108732 | Phase 2 | Feb 1, 2006 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) |
| NCT00113984 | Phase 1 | Jun 8, 2005 | National Cancer Institute (NCI) |
| NCT00096551 | Phase 1 | Nov 1, 2004 | National Cancer Institute (NCI) |
| NCT00087373 | Phase 2 | Jun 1, 2004 | National Cancer Institute (NCI), University of Chicago |
| NCT00072137 | Phase 1 | Oct 1, 2003 | National Cancer Institute (NCI), Rutgers University |
| NCT00060528 | Phase 1/Phase 2 (Phase 2) | May 1, 2003 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00030693 | Phase 1 | Dec 1, 2001 | Icahn School of Medicine at Mount Sinai, National Cancer Institute (NCI) |
| NCT00021424 | Phase 1 | Jun 1, 2001 | National Institute on Deafness and Other Communication Disorders (NIDCD) |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 14 | 14 | 2 | 2001 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2003 |
| Bavarian Nordic | For profit | 1 | 0 | 1 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2006 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2001 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | Government | 1 | 1 | 1 | 2001 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2018 |
12 organizations
Page 1 / 1